How mutant STAT6 affects follicular lymphoma
The Biology of Mutant STAT6 in Follicular Lymphoma
This project looks at how a gene change called STAT6 affects follicular lymphoma to help find better treatments for people with this cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11169832 on NIH RePORTER |
What this research studies
Researchers at the University of Michigan will study how mutations in the STAT6 gene change the behavior of follicular lymphoma cells. They will analyze patient tumor samples and use genomic tools such as DNA/RNA sequencing and ATAC‑seq to see how STAT6 alters gene activity and chromatin accessibility. Lab-grown lymphoma cells and animal models will be used to test how STAT6-mutant tumors respond to different drugs and to identify possible drug targets. The team will relate the laboratory findings to clinical data to better understand which patients might benefit from STAT6-directed approaches.
Who could benefit from this research
Good fit: People with follicular lymphoma—especially those whose tumor testing shows a STAT6 mutation or who have relapsed after standard therapies—would be the most relevant candidates for related future trials or sample donation.
Not a fit: Patients with other lymphoma types that lack STAT6 mutations or those seeking immediate therapeutic benefit may not directly benefit from this lab-focused research.
Why it matters
Potential benefit: If successful, this work could reveal new drug targets or biomarkers that lead to more effective, targeted treatments for people with follicular lymphoma.
How similar studies have performed: Genetic and pathway studies have led to successful targeted treatments in other lymphomas, but directly targeting STAT6 in follicular lymphoma is a relatively new and emerging area.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Malek, Sami Nimer — University of Michigan at Ann Arbor
- Study coordinator: Malek, Sami Nimer
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.